@article{oai:doshisha.repo.nii.ac.jp:00026124,
 author = {冨田, 健司 and Tomita, Kenji},
 issue = {5},
 journal = {同志社商学, Doshisha Shogaku (The Doshisha Business Review)},
 month = {Mar},
 note = {ドラッグ・リポジショニングをオープン・イノベーションの枠組みで考えると，ライセンス・イン（導入）の形態となるが，これまで製薬産業で行われている形態とは異なる。これは既に上市済みの薬から，新しい効能を見つけ出し，別の薬として販売することなのである。他社で使用中の物質特許を使用するが，同じ形で販売するのではなく，価値の再定義を行うこととなる。薬のような知識商品の場合，累積性と状況依存性といった性質が知識にはあるので，価値の再定義を行いやすい。, When one considers drug repositioning within a framework of open innovation, it may be interpreted as a kind of licensing. Yet the contents of both things vary considerably. Under this method, a new effect from an existing drug is discovered and then sold as another (new) drug. The company utilizes spent materials patent in another company. However, the firm does not sell the medicine in the same form and performs a redefinition of its value. The company is thus enabled to perform a redefinition of its value because knowledge has two characteristics such as accumulation and situation dependence, which is the case with a knowledge product such as a drug., 上田慧教授古稀祝賀記念号, Honorable issue in commemoration of Prof. Satoshi Ueda 70 years of age, application/pdf},
 pages = {867--883},
 title = {Redefinition of value through drug repositioning},
 volume = {69},
 year = {2018},
 yomi = {トミタ, ケンジ}
}